Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.

@article{tabuc2003UrokinasetypePA,
  title={Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.},
  author={Borut {\vS}tabuc and Jasmina Lipkovska Markovic and Igor Bartenjev and Ivan Vrhovec and Urska Medved and Borut Kocijan{\vc}i{\vc}},
  journal={Oncology reports},
  year={2003},
  volume={10 3},
  pages={
          635-9
        }
}
The urokinase-type plasminogen activator (uPA) and its inhibitors type 1 (PAI-1) and type 2 (PAI-2) are considered to have a key role in the process of invasion and metastasis. We investigated the differences in uPA, PAI-1 and PAI-2 concentrations in primary cutaneous melanoma and normal skin and correlations with well-established melanoma prognostic factors. The study was performed on 43 patients (19 men, 24 women; mean age 57 years) with histologically confirmed primary melanomas <1.5 mm… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target

  • Cellular and Molecular Life Sciences
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1

Dan Ilkovitch, Roberto Carrio, Diana M. Lopez
  • Immunologic research
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

  • Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • 2005